Live symbol workspace

MRK market intelligence

Chart context, AI evidence, sentiment, related news, and verified outcome history are grouped into one asset dossier.

Current $120.89

Trend Flat

Sentiment Neutral

{# Only render the live technical grid when the AI analysis carries real, non-placeholder data. Sentinel payloads (data_status error/collecting, current_price 0) are handled by the Asset Intelligence Dossier below, which degrades to a calm branded empty state instead of "0%" widgets. #}

Detailed Market Analysis

Key Levels

Support

$114.85

Resistance

$126.93

Volume & Momentum

Volume

Weak

0.8x avg

Momentum

0%

Weak

Technical Context

Current price

$120.89

RSI context

50

Market Sentiment

50

Neutral

Stock Metrics

Daily Vol

0%

VIX Est

20

Weekly

0%

Asset Intelligence Dossier

Provider track record

Not enough scored provider calls yet for this asset.

Confidence trend

31%

▲ 1.2 pts vs previous week

Avg confidence across 17 calls in the last 7 days

What sources say

Bearish 1 article

Stock Market Today, June 18: Pfizer Falls as CFO Transition Tests Confidence in 2026 Outlook

Neutral 1 article

Which Pharmaceutical ETF Is Better, VanEck's PPH or Invesco's PJP?

Insider Trading

Refreshing insider trades from FinViz…

Technical Observations

Refreshing technical observations from FinViz...

MRK News Intelligence (8 articles)

AI-curated news influencing MRK price, sentiment, and trend

Explore All MRK News with AI Analysis

Economy

2 months, 4 weeks ago

Strong Results Lifted Merck & Co (MRK) in Q4

TCW funds, an investment management company, released its “TCW Relative Value Large Cap Fund” fourth-quarter 2025 investor letter. A copy …

Impact on MRK: Neutral market sentiment indicated

FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence. High (94%)

View full analysis →

Yahoo Finance 94% confidence

Stocks

3 months, 1 week ago

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

Pharmaceutical giant Pfizer and French partner Valneva on Monday said they planned to seek regulatory approval for a Lyme disease …

Impact on MRK: The announcement is likely to have a positive impact on Pfizer's (PFE) …

Pfizer and Valneva plan to seek regulatory approval for a Lyme disease vaccine after a … High (80%)

View full analysis →

MarketWatch 80% confidence